The global veterinary analgesics/anti-inflammatory (NSAIDs) market size is calculated at USD 2.59 billion in 2025 and is forecasted to reach around USD 4.58 billion by 2034, accelerating at a CAGR of 6.54% from 2025 to 2034. The North America market size surpassed USD 886.95 million in 2024 and is expanding at a CAGR of 6.69% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Volume, by Drug Class
8.1.1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
8.1.1.1. Market Revenue and Volume Forecast
8.1.2. Opioids
8.1.2.1. Market Revenue and Volume Forecast
8.1.3. Adjunctive Analgesics
8.1.3.1. Market Revenue and Volume Forecast
9.1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Volume, by Animal Type
9.1.1. Companion Animals
9.1.1.1. Market Revenue and Volume Forecast
9.1.2. Livestock Animals
9.1.2.1. Market Revenue and Volume Forecast
10.1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Volume, by Route of Administration
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast
10.1.2. Injectable
10.1.2.1. Market Revenue and Volume Forecast
10.1.3. Topical / Transdermal
10.1.3.1. Market Revenue and Volume Forecast
10.1.4. Others
10.1.4.1. Market Revenue and Volume Forecast
11.1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Volume, by Indication
11.1.1. Post-operative Pain
11.1.1.1. Market Revenue and Volume Forecast
11.1.2. Musculoskeletal Disorders (e.g., osteoarthritis)
11.1.2.1. Market Revenue and Volume Forecast
11.1.3. Colic Pain (horses)
11.1.3.1. Market Revenue and Volume Forecast
11.1.4. Fever & Inflammation Management
11.1.4.1. Market Revenue and Volume Forecast
11.1.5. Infectious Disease–associated Pain
11.1.5.1. Market Revenue and Volume Forecast
12.1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Volume, by Distribution Channel
12.1.1. Veterinary Clinics & Hospitals
12.1.1.1. Market Revenue and Volume Forecast
12.1.2. Retail Pharmacies
12.1.2.1. Market Revenue and Volume Forecast
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Volume Forecast
12.1.4. Feed Stores / Agricultural Cooperatives
12.1.4.1. Market Revenue and Volume Forecast
13.1. Veterinary Analgesics/Anti-Inflammatory (NSAIDs) Market Revenue and Volume, by End User
13.1.1. Veterinarians
13.1.1.1. Market Revenue and Volume Forecast
13.1.2. Pet Owners
13.1.2.1. Market Revenue and Volume Forecast
13.1.3. Livestock Owners / Farmers
13.1.3.1. Market Revenue and Volume Forecast
13.1.4. Animal Welfare Organizations
13.1.4.1. Market Revenue and Volume Forecast
14.1. North America
14.1.1. Market Revenue and Volume Forecast, by Drug Class
14.1.2. Market Revenue and Volume Forecast, by Animal Type
14.1.3. Market Revenue and Volume Forecast, by Route of Administration
14.1.4. Market Revenue and Volume Forecast, by Indication
14.1.5. Market Revenue and Volume Forecast, by Distribution Channel
14.1.6. Market Revenue and Volume Forecast, by End User
14.1.7. U.S.
14.1.7.1. Market Revenue and Volume Forecast, by Drug Class
14.1.7.2. Market Revenue and Volume Forecast, by Animal Type
14.1.7.3. Market Revenue and Volume Forecast, by Route of Administration
14.1.7.4. Market Revenue and Volume Forecast, by Indication
14.1.8. Market Revenue and Volume Forecast, by Distribution Channel
14.1.8.1. Market Revenue and Volume Forecast, by End User
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Volume Forecast, by Drug Class
14.1.9.2. Market Revenue and Volume Forecast, by Animal Type
14.1.9.3. Market Revenue and Volume Forecast, by Route of Administration
14.1.9.4. Market Revenue and Volume Forecast, by Indication
14.1.10. Market Revenue and Volume Forecast, by Distribution Channel
14.1.11. Market Revenue and Volume Forecast, by End User
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Volume Forecast, by Drug Class
14.2.2. Market Revenue and Volume Forecast, by Animal Type
14.2.3. Market Revenue and Volume Forecast, by Route of Administration
14.2.4. Market Revenue and Volume Forecast, by Indication
14.2.5. Market Revenue and Volume Forecast, by Distribution Channel
14.2.6. Market Revenue and Volume Forecast, by End User
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Volume Forecast, by Drug Class
14.2.8.2. Market Revenue and Volume Forecast, by Animal Type
14.2.8.3. Market Revenue and Volume Forecast, by Route of Administration
14.2.9. Market Revenue and Volume Forecast, by Indication
14.2.10. Market Revenue and Volume Forecast, by Distribution Channel
14.2.10.1. Market Revenue and Volume Forecast, by End User
14.2.11. Germany
14.2.11.1. Market Revenue and Volume Forecast, by Drug Class
14.2.11.2. Market Revenue and Volume Forecast, by Animal Type
14.2.11.3. Market Revenue and Volume Forecast, by Route of Administration
14.2.12. Market Revenue and Volume Forecast, by Indication
14.2.13. Market Revenue and Volume Forecast, by Distribution Channel
14.2.14. Market Revenue and Volume Forecast, by End User
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Volume Forecast, by Drug Class
14.2.15.2. Market Revenue and Volume Forecast, by Animal Type
14.2.15.3. Market Revenue and Volume Forecast, by Route of Administration
14.2.15.4. Market Revenue and Volume Forecast, by Indication
14.2.16. Market Revenue and Volume Forecast, by Distribution Channel
14.2.16.1. Market Revenue and Volume Forecast, by End User
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Volume Forecast, by Drug Class
14.2.17.2. Market Revenue and Volume Forecast, by Animal Type
14.2.17.3. Market Revenue and Volume Forecast, by Route of Administration
14.2.17.4. Market Revenue and Volume Forecast, by Indication
14.2.18. Market Revenue and Volume Forecast, by Distribution Channel
14.2.18.1. Market Revenue and Volume Forecast, by End User
14.3. APAC
14.3.1. Market Revenue and Volume Forecast, by Drug Class
14.3.2. Market Revenue and Volume Forecast, by Animal Type
14.3.3. Market Revenue and Volume Forecast, by Route of Administration
14.3.4. Market Revenue and Volume Forecast, by Indication
14.3.5. Market Revenue and Volume Forecast, by Distribution Channel
14.3.6. Market Revenue and Volume Forecast, by End User
14.3.7. India
14.3.7.1. Market Revenue and Volume Forecast, by Drug Class
14.3.7.2. Market Revenue and Volume Forecast, by Animal Type
14.3.7.3. Market Revenue and Volume Forecast, by Route of Administration
14.3.7.4. Market Revenue and Volume Forecast, by Indication
14.3.8. Market Revenue and Volume Forecast, by Distribution Channel
14.3.9. Market Revenue and Volume Forecast, by End User
14.3.10. China
14.3.10.1. Market Revenue and Volume Forecast, by Drug Class
14.3.10.2. Market Revenue and Volume Forecast, by Animal Type
14.3.10.3. Market Revenue and Volume Forecast, by Route of Administration
14.3.10.4. Market Revenue and Volume Forecast, by Indication
14.3.11. Market Revenue and Volume Forecast, by Distribution Channel
14.3.11.1. Market Revenue and Volume Forecast, by End User
14.3.12. Japan
14.3.12.1. Market Revenue and Volume Forecast, by Drug Class
14.3.12.2. Market Revenue and Volume Forecast, by Animal Type
14.3.12.3. Market Revenue and Volume Forecast, by Route of Administration
14.3.12.4. Market Revenue and Volume Forecast, by Indication
14.3.12.5. Market Revenue and Volume Forecast, by Distribution Channel
14.3.12.6. Market Revenue and Volume Forecast, by End User
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Volume Forecast, by Drug Class
14.3.13.2. Market Revenue and Volume Forecast, by Animal Type
14.3.13.3. Market Revenue and Volume Forecast, by Route of Administration
14.3.13.4. Market Revenue and Volume Forecast, by Indication
14.3.13.5. Market Revenue and Volume Forecast, by Distribution Channel
14.3.13.6. Market Revenue and Volume Forecast, by End User
14.4. MEA
14.4.1. Market Revenue and Volume Forecast, by Drug Class
14.4.2. Market Revenue and Volume Forecast, by Animal Type
14.4.3. Market Revenue and Volume Forecast, by Route of Administration
14.4.4. Market Revenue and Volume Forecast, by Indication
14.4.5. Market Revenue and Volume Forecast, by Distribution Channel
14.4.6. Market Revenue and Volume Forecast, by End User
14.4.7. GCC
14.4.7.1. Market Revenue and Volume Forecast, by Drug Class
14.4.7.2. Market Revenue and Volume Forecast, by Animal Type
14.4.7.3. Market Revenue and Volume Forecast, by Route of Administration
14.4.7.4. Market Revenue and Volume Forecast, by Indication
14.4.8. Market Revenue and Volume Forecast, by Distribution Channel
14.4.9. Market Revenue and Volume Forecast, by End User
14.4.10. North Africa
14.4.10.1. Market Revenue and Volume Forecast, by Drug Class
14.4.10.2. Market Revenue and Volume Forecast, by Animal Type
14.4.10.3. Market Revenue and Volume Forecast, by Route of Administration
14.4.10.4. Market Revenue and Volume Forecast, by Indication
14.4.11. Market Revenue and Volume Forecast, by Distribution Channel
14.4.12. Market Revenue and Volume Forecast, by End User
14.4.13. South Africa
14.4.13.1. Market Revenue and Volume Forecast, by Drug Class
14.4.13.2. Market Revenue and Volume Forecast, by Animal Type
14.4.13.3. Market Revenue and Volume Forecast, by Route of Administration
14.4.13.4. Market Revenue and Volume Forecast, by Indication
14.4.13.5. Market Revenue and Volume Forecast, by Distribution Channel
14.4.13.6. Market Revenue and Volume Forecast, by End User
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Volume Forecast, by Drug Class
14.4.14.2. Market Revenue and Volume Forecast, by Animal Type
14.4.14.3. Market Revenue and Volume Forecast, by Route of Administration
14.4.14.4. Market Revenue and Volume Forecast, by Indication
14.4.14.5. Market Revenue and Volume Forecast, by Distribution Channel
14.4.14.6. Market Revenue and Volume Forecast, by End User
14.5. Latin America
14.5.1. Market Revenue and Volume Forecast, by Drug Class
14.5.2. Market Revenue and Volume Forecast, by Animal Type
14.5.3. Market Revenue and Volume Forecast, by Route of Administration
14.5.4. Market Revenue and Volume Forecast, by Indication
14.5.5. Market Revenue and Volume Forecast, by Distribution Channel
14.5.6. Market Revenue and Volume Forecast, by End User
14.5.7. Brazil
14.5.7.1. Market Revenue and Volume Forecast, by Drug Class
14.5.7.2. Market Revenue and Volume Forecast, by Animal Type
14.5.7.3. Market Revenue and Volume Forecast, by Route of Administration
14.5.7.4. Market Revenue and Volume Forecast, by Indication
14.5.8. Market Revenue and Volume Forecast, by Distribution Channel
14.5.8.1. Market Revenue and Volume Forecast, by End User
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Volume Forecast, by Drug Class
14.5.9.2. Market Revenue and Volume Forecast, by Animal Type
14.5.9.3. Market Revenue and Volume Forecast, by Route of Administration
14.5.9.4. Market Revenue and Volume Forecast, by Indication
14.5.9.5. Market Revenue and Volume Forecast, by Distribution Channel
14.5.9.6. Market Revenue and Volume Forecast, by End User
15.1. Zoetis Inc.
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Boehringer Ingelheim Animal Health
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Elanco Animal Health
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Dechra Pharmaceuticals
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Vetoquinol
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Phibro Animal Health
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Bimeda Animal Health
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Huvepharma
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Zydus Animal Health
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Ourofino Saúde Animal
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description